Active Pharmaceutical Ingredient (API) Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx); By Region (U.S., Canada, Mexico, Rest of North America, UK, France, Germany, Italy, Spain, Benelux Union, Nordic Countries , Rest of Europe, China, Japan, India, South Korea, Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia, Rest of Asia Pacific, Brazil, Argentina Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, Southern Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Global Active Pharmaceutical Ingredient (API) Market was valued at US$ 168.72 billion in 2018 and is expected to reach US$ 265.63 billion by 2027, growing at an estimated CAGR of 5.2% over the forecast period.
The key drivers of the Active Pharmaceutical Ingredient (API) Market are advancements in the technology for manufacturing of active pharmaceutical ingredients (API), expansion of the biopharmaceutical industry and an increase in the geriatric population. The rising prevalence of infectious diseases and hospital-acquired infections is expected to drive the growth of the active pharmaceutical ingredients market over the forecast period. Growing prevalence of congenital heart disease is also serving as a factor of growth for the overall market. Epidemiological studies have shown how lifestyle patterns such as smoking and dietary changes-which can lead to obesity-are associated with increased disease risk. Hence rising obesity prevalence is expected to drive demand for active pharmaceutical ingredients. active pharmaceutical ingredients are also used as conjugates for antibody drugs (ADCs). In conjunction with monoclonal antibodies and biologically active cancer drugs, ADCs are important and effective treatment modalities. active pharmaceutical ingredients efficiently target the cancer cells, thus reducing drug exposure to healthy tissues.
Type Insights
Active Pharmaceutical Ingredient (API) Market has been segmented, based on type, as innovative and generic. As an API advances from early clinical improvement through clinical preliminaries and on to commercialization, the first engineered course may not generally be the most productive, maintainable or practical procedure as the size of assembling raises. Moreover, mystified or risky sciences or costly key intermediates may forestall redistributing or insourcing of creation, or may even make the procedure too uneconomical to even think about allowing the advancement program to proceed.
Manufacturer Insights
Pharmaceutical assembling happens in two general advances. To start with, firms convert crude materials into APIs. At that point, firms make last plans by blending APIs and excipients, squeezing the blend into tablets, or filling cases or getting ready arrangements, and afterward bundling the item for the purchaser showcase. Firms either sell APIs on the open market ("vendor market"). Firms that make both APIs and last particulars will normally still purchase and sell APIs on the shipper showcase.
APIs are fundamental parts of both the quality and the expense of pharmaceutical items. Simple access to quality active pharmaceutical ingredients at low expenses for finalised item makers ought to be sought after as a general wellbeing objective considering Universal Health Coverage. This requires taking a look at the active pharmaceutical ingredients showcase from supportability and quality just as from a value viewpoint. As each particular API advertise is assorted, each Active Pharmaceutical Ingredient (API) Market ought to be analysed exclusively to decide whether it is serious with moderate costs.
Synthesis Insights
Active Pharmaceutical Ingredient (API) Market has been segmented, based on synthesis, as synthetic and biotech. Although present-day reagents, for example, hypervalent iodine and triflic corrosive speak to truly significant augmentations to the scientific experts' collection they are additionally usually costly and hard to source at scale. What's more, the waste streams created through their utilization would likewise be troublesome and exorbitant to arrange. This appropriately prompts an intriguing relationship that is regularly experienced in inventive work utilizing new advancements where a general outlook exists to likewise test the restrictions of present-day reagent reciprocals notwithstanding the gear. From a scholarly point of view, this is a positive and helpful commitment to the movement of the subject, be that as it may, this can fundamentally limit the translational estimation of the approach as for selection or advantageous take-up by industry.
Product Insights
Active Pharmaceutical Ingredient (API) Market has been segmented, based on product, as mAb, hormone, biosimilar. Most critical impacts coming about because of presentation to pharmaceutical specialists are the consequence of intense pharmacological impacts. The advancement of antagonistic pharmacological impacts isn't the main issue related to presentation to pharmaceuticals. Respiratory sharpening has been noted corresponding to presentation to a few mixes. Two gatherings of mixes have been especially implicated: penicillin and cephalosporin antibiotics and enzymes.
Drug Insights
The active pharmaceutical ingredients market can be categorized into two segments: prescription (Rx) drugs and over the counter (OTC) products, based on the type of drug, the prescription drugs segment is expected to account for the biggest market share of the APIs in 2019. Due to the increasing prevalence of target diseases the demand for drugs falling under this category has risen significantly in recent years. In addition, the largest proportion of the prescription drugs market may also be due to the increased focus of innovator companies on the production of specialty drugs and healthcare affordability. Implementing major federal changes to improve healthcare access, especially in the US, has increased both conventional and specialty drug consumption. Inflation has also played a key role in stepping up revenue from prescription drug sales, particularly specialty drugs.
Region Insights
North America, led by Europe, is expected to dominate the active pharmaceutical ingredient (API) market in 2019. The main factors driving the overall growth of the active pharmaceutical ingredients market in this area include the growing incidence of preventable chronic diseases, increasing policy emphasis on generic drugs, increasing demand for biologics and specialty drugs, and technological advances in active pharmaceutical ingredients manufacturing processes. Due to a combination of economic and healthcare severity initiatives and the launch of low-cost, generic versions of branded drugs, this market segment is expected to grow at moderate pace.
Active Pharmaceutical Ingredient (API) Market Revenue & Forecast, (US$ Billion), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of active pharmaceutical ingredient (API) market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The major market players in active pharmaceutical ingredient (API) market include AbbVie Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Cipla Inc.; Boehringer Ingelheim International GmbH; Merck & Co., Inc.; Sun Pharmaceutical Industries Ltd.; Bristol-Myers Squibb Company; Albemarle Corporation; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd.
Active Pharmaceutical Ingredient Market:
- By Type
- Innovative
- Generic
- By Manufacturer
- Captive
- Merchant
- By Synthesis
- Synthetic
- Biotech
- By Product
- mAb
- Hormone
- Biosimilar
- By Drug
- OTC
- Rx
- By Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Active Pharmaceutical Ingredient Market
6. Market Synopsis:
Active Pharmaceutical Ingredient Market
7. Active Pharmaceutical Ingredient Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Active Pharmaceutical Ingredient Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Active Pharmaceutical Ingredient Market
7.6. Porter’s
Five Force Analysis
8. Global Active Pharmaceutical Ingredient Market Analysis and
Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Active Pharmaceutical Ingredient Market Revenue (US$ Mn)
8.2. Global
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Innovative
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Generic
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Active Pharmaceutical Ingredient Market Analysis and
Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
9.2.1. Captive
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Merchant
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Manufacturer
10. Global Active Pharmaceutical Ingredient Market Analysis and
Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
10.2.1. Synthetic
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Biotech
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By
Synthesis
11. Global Active Pharmaceutical Ingredient Market Analysis and
Forecasts, 2019 – 2027
11.1. Overview
11.2. Global
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
11.2.1. mAb
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2013 – 2018
11.2.1.3. Market
Forecast, 2019 – 2027
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2013 – 2018
11.2.1.5.1.2. Market
Forecast, 2019 – 2027
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2013 – 2018
11.2.1.5.2.2. Market
Forecast, 2019 – 2027
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2013 – 2018
11.2.1.5.3.2. Market
Forecast, 2019 – 2027
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2013 – 2018
11.2.1.5.4.2. Market
Forecast, 2019 – 2027
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2013 – 2018
11.2.1.5.5.2. Market
Forecast, 2019 – 2027
11.2.2. Hormone
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2013 – 2018
11.2.2.3. Market
Forecast, 2019 – 2027
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2013 – 2018
11.2.2.5.1.2. Market
Forecast, 2019 – 2027
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2013 – 2018
11.2.2.5.2.2. Market
Forecast, 2019 – 2027
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2013 – 2018
11.2.2.5.3.2. Market
Forecast, 2019 – 2027
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2013 – 2018
11.2.2.5.4.2. Market
Forecast, 2019 – 2027
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2013 – 2018
11.2.2.5.5.2. Market
Forecast, 2019 – 2027
11.2.3. Biosimilar
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2013 – 2018
11.2.3.3. Market
Forecast, 2019 – 2027
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2013 – 2018
11.2.3.5.1.2. Market
Forecast, 2019 – 2027
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2013 – 2018
11.2.3.5.2.2. Market
Forecast, 2019 – 2027
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2013 – 2018
11.2.3.5.3.2. Market
Forecast, 2019 – 2027
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2013 – 2018
11.2.3.5.4.2. Market
Forecast, 2019 – 2027
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2013 – 2018
11.2.3.5.5.2. Market
Forecast, 2019 – 2027
11.3. Key
Segment for Channeling Investments
11.3.1. By
Product
12. Global Active Pharmaceutical Ingredient Market Analysis and
Forecasts, 2019 – 2027
12.1. Overview
12.2. Global
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
12.2.1. OTC
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2013 – 2018
12.2.1.3. Market
Forecast, 2019 – 2027
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2013 – 2018
12.2.1.5.1.2. Market
Forecast, 2019 – 2027
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2013 – 2018
12.2.1.5.2.2. Market
Forecast, 2019 – 2027
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2013 – 2018
12.2.1.5.3.2. Market
Forecast, 2019 – 2027
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2013 – 2018
12.2.1.5.4.2. Market
Forecast, 2019 – 2027
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2013 – 2018
12.2.1.5.5.2. Market
Forecast, 2019 – 2027
12.2.2. Rx
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2013 – 2018
12.2.2.3. Market
Forecast, 2019 – 2027
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2013 – 2018
12.2.2.5.1.2. Market
Forecast, 2019 – 2027
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2013 – 2018
12.2.2.5.2.2. Market
Forecast, 2019 – 2027
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2013 – 2018
12.2.2.5.3.2. Market
Forecast, 2019 – 2027
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2013 – 2018
12.2.2.5.4.2. Market
Forecast, 2019 – 2027
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2013 – 2018
12.2.2.5.5.2. Market
Forecast, 2019 – 2027
12.3. Key
Segment for Channeling Investments
12.3.1. By Drug
13. North America Active Pharmaceutical Ingredient Market
Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. North
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn)
13.2. North
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Type
13.2.1. Innovative
13.2.2. Generic
13.3. North
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Manufacturer
13.3.1. Captive
13.3.2. Merchant
13.4. North
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Synthesis
13.4.1. Synthetic
13.4.2. Biotech
13.5. North
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Product
13.5.1. mAb
13.5.2. Hormone
13.5.3. Biosimilar
13.6. North
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Drug
13.6.1. OTC
13.6.2. Rx
13.7. North
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Country
13.7.1. U.S
13.7.1.1. U.S
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
13.7.1.1.1. Innovative
13.7.1.1.2. Generic
13.7.1.2. U.S
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
13.7.1.2.1. Captive
13.7.1.2.2. Merchant
13.7.1.3. U.S
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
13.7.1.3.1. Synthetic
13.7.1.3.2. Biotech
13.7.1.4. U.S
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
13.7.1.4.1. mAb
13.7.1.4.2. Hormone
13.7.1.4.3. Biosimilar
13.7.1.5. U.S
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.1.5.1. OTC
13.7.1.5.2. Rx
13.7.2. Canada
13.7.2.1. Canada
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
13.7.2.1.1. Innovative
13.7.2.1.2. Generic
13.7.2.2. Canada
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
13.7.2.2.1. Captive
13.7.2.2.2. Merchant
13.7.2.3. Canada
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
13.7.2.3.1. Synthetic
13.7.2.3.2. Biotech
13.7.2.4. Canada
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
13.7.2.4.1. mAb
13.7.2.4.2. Hormone
13.7.2.4.3. Biosimilar
13.7.2.5. Canada
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.2.5.1. OTC
13.7.2.5.2. Rx
13.7.3. Mexico
13.7.3.1. Mexico
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
13.7.3.1.1. Innovative
13.7.3.1.2. Generic
13.7.3.2. Mexico
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
13.7.3.2.1. Captive
13.7.3.2.2. Merchant
13.7.3.3. Mexico
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
13.7.3.3.1. Synthetic
13.7.3.3.2. Biotech
13.7.3.4. Mexico
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
13.7.3.4.1. mAb
13.7.3.4.2. Hormone
13.7.3.4.3. Biosimilar
13.7.3.5. Mexico
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.3.5.1. OTC
13.7.3.5.2. Rx
13.7.4. Rest of
North America
13.7.4.1. Rest
of North America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.4.1.1. Innovative
13.7.4.1.2. Generic
13.7.4.2. Rest
of North America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Manufacturer
13.7.4.2.1. Captive
13.7.4.2.2. Merchant
13.7.4.3. Rest
of North America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Synthesis
13.7.4.3.1. Synthetic
13.7.4.3.2. Biotech
13.7.4.4. Rest
of North America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Product
13.7.4.4.1. mAb
13.7.4.4.2. Hormone
13.7.4.4.3. Biosimilar
13.7.4.5. Rest
of North America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Drug
13.7.4.5.1. OTC
13.7.4.5.2. Rx
13.8. Key
Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By Type
13.8.3. By
Manufacturer
13.8.4. By
Synthesis
13.8.5. By
Product
13.8.6. By Drug
14. Europe Active Pharmaceutical Ingredient Market Analysis and
Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Europe
Active Pharmaceutical Ingredient Market Revenue (US$ Mn)
14.2. Europe
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Innovative
14.2.2. Generic
14.3. Europe
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
14.3.1. Captive
14.3.2. Merchant
14.4. Europe
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
14.4.1. Synthetic
14.4.2. Biotech
14.5. Europe
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
14.5.1. mAb
14.5.2. Hormone
14.5.3. Biosimilar
14.6. Europe
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
14.6.1. OTC
14.6.2. Rx
14.7. Europe
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.1. France
14.7.1.1. France
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
14.7.1.1.1. Innovative
14.7.1.1.2. Generic
14.7.1.2. France
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
14.7.1.2.1. Captive
14.7.1.2.2. Merchant
14.7.1.3. France
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
14.7.1.3.1. Synthetic
14.7.1.3.2. Biotech
14.7.1.4. France
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
14.7.1.4.1. mAb
14.7.1.4.2. Hormone
14.7.1.4.3. Biosimilar
14.7.1.5. France
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.1.5.1. OTC
14.7.1.5.2. Rx
14.7.2. The UK
14.7.2.1. The
UK Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.2.1.1. Innovative
14.7.2.1.2. Generic
14.7.2.2. The
UK Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
14.7.2.2.1. Captive
14.7.2.2.2. Merchant
14.7.2.3. The
UK Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
14.7.2.3.1. Synthetic
14.7.2.3.2. Biotech
14.7.2.4. The
UK Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
14.7.2.4.1. mAb
14.7.2.4.2. Hormone
14.7.2.4.3. Biosimilar
14.7.2.5. The
UK Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Drug
14.7.2.5.1. OTC
14.7.2.5.2. Rx
14.7.3. Spain
14.7.3.1. Spain
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
14.7.3.1.1. Innovative
14.7.3.1.2. Generic
14.7.3.2. Spain
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
14.7.3.2.1. Captive
14.7.3.2.2. Merchant
14.7.3.3. Spain
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
14.7.3.3.1. Synthetic
14.7.3.3.2. Biotech
14.7.3.4. Spain
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
14.7.3.4.1. mAb
14.7.3.4.2. Hormone
14.7.3.4.3. Biosimilar
14.7.3.5. Spain
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.3.5.1. OTC
14.7.3.5.2. Rx
14.7.4. Germany
14.7.4.1. Germany
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
14.7.4.1.1. Innovative
14.7.4.1.2. Generic
14.7.4.2. Germany
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
14.7.4.2.1. Captive
14.7.4.2.2. Merchant
14.7.4.3. Germany
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
14.7.4.3.1. Synthetic
14.7.4.3.2. Biotech
14.7.4.4. Germany
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
14.7.4.4.1. mAb
14.7.4.4.2. Hormone
14.7.4.4.3. Biosimilar
14.7.4.5. Germany
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.4.5.1. OTC
14.7.4.5.2. Rx
14.7.5. Italy
14.7.5.1. Italy
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
14.7.5.1.1. Innovative
14.7.5.1.2. Generic
14.7.5.2. Italy
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
14.7.5.2.1. Captive
14.7.5.2.2. Merchant
14.7.5.3. Italy
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
14.7.5.3.1. Synthetic
14.7.5.3.2. Biotech
14.7.5.4. Italy
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
14.7.5.4.1. mAb
14.7.5.4.2. Hormone
14.7.5.4.3. Biosimilar
14.7.5.5. Italy
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.5.5.1. OTC
14.7.5.5.2. Rx
14.7.6. Nordic
Countries
14.7.6.1. Nordic
Countries Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.6.1.1. Innovative
14.7.6.1.2. Generic
14.7.6.2. Nordic
Countries Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Manufacturer
14.7.6.2.1. Captive
14.7.6.2.2. Merchant
14.7.6.3. Nordic
Countries Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Synthesis
14.7.6.3.1. Synthetic
14.7.6.3.2. Biotech
14.7.6.4. Nordic
Countries Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Product
14.7.6.4.1. mAb
14.7.6.4.2. Hormone
14.7.6.4.3. Biosimilar
14.7.6.5. Nordic
Countries Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Drug
14.7.6.5.1. OTC
14.7.6.5.2. Rx
14.7.6.6. Nordic
Countries Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux
Union Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Type
14.7.7.1.1. Innovative
14.7.7.1.2. Generic
14.7.7.2. Benelux
Union Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Manufacturer
14.7.7.2.1. Captive
14.7.7.2.2. Merchant
14.7.7.3. Benelux
Union Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Synthesis
14.7.7.3.1. Synthetic
14.7.7.3.2. Biotech
14.7.7.4. Benelux
Union Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Product
14.7.7.4.1. mAb
14.7.7.4.2. Hormone
14.7.7.4.3. Biosimilar
14.7.7.5. Benelux
Union Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Drug
14.7.7.5.1. OTC
14.7.7.5.2. Rx
14.7.7.6. Benelux
Union Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The
Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest
of Europe Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.8.1.1. Innovative
14.7.8.1.2. Generic
14.7.8.2. Rest
of Europe Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Manufacturer
14.7.8.2.1. Captive
14.7.8.2.2. Merchant
14.7.8.3. Rest
of Europe Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Synthesis
14.7.8.3.1. Synthetic
14.7.8.3.2. Biotech
14.7.8.4. Rest
of Europe Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Product
14.7.8.4.1. mAb
14.7.8.4.2. Hormone
14.7.8.4.3. Biosimilar
14.7.8.5. Rest
of Europe Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Drug
14.7.8.5.1. OTC
14.7.8.5.2. Rx
14.8. Key
Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By Type
14.8.3. By
Manufacturer
14.8.4. By
Synthesis
14.8.5. By
Product
14.8.6. By Drug
15. Asia Pacific Active Pharmaceutical Ingredient Market Analysis
and Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Asia
Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn)
15.2. Asia
Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Type
15.2.1. Innovative
15.2.2. Generic
15.3. Asia
Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Manufacturer
15.3.1. Captive
15.3.2. Merchant
15.4. Asia
Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Synthesis
15.4.1. Synthetic
15.4.2. Biotech
15.5. Asia
Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Product
15.5.1. mAb
15.5.2. Hormone
15.5.3. Biosimilar
15.6. Asia
Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Drug
15.6.1. OTC
15.6.2. Rx
15.7. Asia
Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Country
15.7.1. China
15.7.1.1. China
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
15.7.1.1.1. Innovative
15.7.1.1.2. Generic
15.7.1.2. China
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
15.7.1.2.1. Captive
15.7.1.2.2. Merchant
15.7.1.3. China
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
15.7.1.3.1. Synthetic
15.7.1.3.2. Biotech
15.7.1.4. China
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
15.7.1.4.1. mAb
15.7.1.4.2. Hormone
15.7.1.4.3. Biosimilar
15.7.1.5. China
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.1.5.1. OTC
15.7.1.5.2. Rx
15.7.2. Japan
15.7.2.1. Japan
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
15.7.2.1.1. Innovative
15.7.2.1.2. Generic
15.7.2.2. Japan
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
15.7.2.2.1. Captive
15.7.2.2.2. Merchant
15.7.2.3. Japan
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
15.7.2.3.1. Synthetic
15.7.2.3.2. Biotech
15.7.2.4. Japan
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
15.7.2.4.1. mAb
15.7.2.4.2. Hormone
15.7.2.4.3. Biosimilar
15.7.2.5. Japan
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.2.5.1. OTC
15.7.2.5.2. Rx
15.7.3. India
15.7.3.1. India
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
15.7.3.1.1. Innovative
15.7.3.1.2. Generic
15.7.3.2. India
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
15.7.3.2.1. Captive
15.7.3.2.2. Merchant
15.7.3.3. India
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
15.7.3.3.1. Synthetic
15.7.3.3.2. Biotech
15.7.3.4. India
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
15.7.3.4.1. mAb
15.7.3.4.2. Hormone
15.7.3.4.3. Biosimilar
15.7.3.5. India
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.3.5.1. OTC
15.7.3.5.2. Rx
15.7.4. New
Zealand
15.7.4.1. New
Zealand Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Type
15.7.4.1.1. Innovative
15.7.4.1.2. Generic
15.7.4.2. New
Zealand Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Manufacturer
15.7.4.2.1. Captive
15.7.4.2.2. Merchant
15.7.4.3. New
Zealand Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Synthesis
15.7.4.3.1. Synthetic
15.7.4.3.2. Biotech
15.7.4.4. New
Zealand Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Product
15.7.4.4.1. mAb
15.7.4.4.2. Hormone
15.7.4.4.3. Biosimilar
15.7.4.5. New
Zealand Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Drug
15.7.4.5.1. OTC
15.7.4.5.2. Rx
15.7.5. Australia
15.7.5.1. Australia
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
15.7.5.1.1. Innovative
15.7.5.1.2. Generic
15.7.5.2. Australia
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
15.7.5.2.1. Captive
15.7.5.2.2. Merchant
15.7.5.3. Australia
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
15.7.5.3.1. Synthetic
15.7.5.3.2. Biotech
15.7.5.4. Australia
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
15.7.5.4.1. mAb
15.7.5.4.2. Hormone
15.7.5.4.3. Biosimilar
15.7.5.5. Australia
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.5.5.1. OTC
15.7.5.5.2. Rx
15.7.6. South
Korea
15.7.6.1. South
Korea Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Type
15.7.6.1.1. Innovative
15.7.6.1.2. Generic
15.7.6.2. South
Korea Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Manufacturer
15.7.6.2.1. Captive
15.7.6.2.2. Merchant
15.7.6.3. South
Korea Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Synthesis
15.7.6.3.1. Synthetic
15.7.6.3.2. Biotech
15.7.6.4. South
Korea Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Product
15.7.6.4.1. mAb
15.7.6.4.2. Hormone
15.7.6.4.3. Biosimilar
15.7.6.5. South
Korea Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Drug
15.7.6.5.1. OTC
15.7.6.5.2. Rx
15.7.7. Southeast
Asia
15.7.7.1. Southeast
Asia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Type
15.7.7.1.1. Innovative
15.7.7.1.2. Generic
15.7.7.2. Southeast
Asia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
15.7.7.2.1. Captive
15.7.7.2.2. Merchant
15.7.7.3. Southeast
Asia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
15.7.7.3.1. Synthetic
15.7.7.3.2. Biotech
15.7.7.4. Southeast
Asia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
15.7.7.4.1. mAb
15.7.7.4.2. Hormone
15.7.7.4.3. Biosimilar
15.7.7.5. Southeast
Asia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Drug
15.7.7.5.1. OTC
15.7.7.5.2. Rx
15.7.7.6. Southeast
Asia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest
of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest
of Asia Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.8.1.1. Innovative
15.7.8.1.2. Generic
15.7.8.2. Rest
of Asia Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Manufacturer
15.7.8.2.1. Captive
15.7.8.2.2. Merchant
15.7.8.3. Rest
of Asia Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Synthesis
15.7.8.3.1. Synthetic
15.7.8.3.2. Biotech
15.7.8.4. Rest
of Asia Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Product
15.7.8.4.1. mAb
15.7.8.4.2. Hormone
15.7.8.4.3. Biosimilar
15.7.8.5. Rest
of Asia Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Drug
15.7.8.5.1. OTC
15.7.8.5.2. Rx
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By Type
15.8.3. By
Manufacturer
15.8.4. By
Synthesis
15.8.5. By
Product
15.8.6. By Drug
16. Middle East and Africa Active Pharmaceutical Ingredient
Market Analysis and Forecasts, 2019 - 2027
16.1. Overview
16.1.1. Middle
East and Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn)
16.2. Middle
East and Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Type
16.2.1. Innovative
16.2.2. Generic
16.3. Middle
East and Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Manufacturer
16.3.1. Captive
16.3.2. Merchant
16.4. Middle
East and Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Synthesis
16.4.1. Synthetic
16.4.2. Biotech
16.5. Middle
East and Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Product
16.5.1. mAb
16.5.2. Hormone
16.5.3. Biosimilar
16.6. Middle
East and Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Drug
16.6.1. OTC
16.6.2. Rx
16.7. Middle
East and Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi
Arabia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Type
16.7.1.1.1. Innovative
16.7.1.1.2. Generic
16.7.1.2. Saudi
Arabia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Manufacturer
16.7.1.2.1. Captive
16.7.1.2.2. Merchant
16.7.1.3. Saudi
Arabia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Synthesis
16.7.1.3.1. Synthetic
16.7.1.3.2. Biotech
16.7.1.4. Saudi
Arabia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Product
16.7.1.4.1. mAb
16.7.1.4.2. Hormone
16.7.1.4.3. Biosimilar
16.7.1.5. Saudi
Arabia Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Drug
16.7.1.5.1. OTC
16.7.1.5.2. Rx
16.7.2. UAE
16.7.2.1. UAE
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
16.7.2.1.1. Innovative
16.7.2.1.2. Generic
16.7.2.2. UAE
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
16.7.2.2.1. Captive
16.7.2.2.2. Merchant
16.7.2.3. UAE
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
16.7.2.3.1. Synthetic
16.7.2.3.2. Biotech
16.7.2.4. UAE
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
16.7.2.4.1. mAb
16.7.2.4.2. Hormone
16.7.2.4.3. Biosimilar
16.7.2.5. UAE
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.2.5.1. OTC
16.7.2.5.2. Rx
16.7.3. Egypt
16.7.3.1. Egypt
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
16.7.3.1.1. Innovative
16.7.3.1.2. Generic
16.7.3.2. Egypt
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
16.7.3.2.1. Captive
16.7.3.2.2. Merchant
16.7.3.3. Egypt
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
16.7.3.3.1. Synthetic
16.7.3.3.2. Biotech
16.7.3.4. Egypt
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
16.7.3.4.1. mAb
16.7.3.4.2. Hormone
16.7.3.4.3. Biosimilar
16.7.3.5. Egypt
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.3.5.1. OTC
16.7.3.5.2. Rx
16.7.4. Kuwait
16.7.4.1. Kuwait
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
16.7.4.1.1. Innovative
16.7.4.1.2. Generic
16.7.4.2. Kuwait
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
16.7.4.2.1. Captive
16.7.4.2.2. Merchant
16.7.4.3. Kuwait
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
16.7.4.3.1. Synthetic
16.7.4.3.2. Biotech
16.7.4.4. Kuwait
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
16.7.4.4.1. mAb
16.7.4.4.2. Hormone
16.7.4.4.3. Biosimilar
16.7.4.5. Kuwait
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.4.5.1. OTC
16.7.4.5.2. Rx
16.7.5. South
Africa
16.7.5.1. South
Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Type
16.7.5.1.1. Innovative
16.7.5.1.2. Generic
16.7.5.2. South
Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Manufacturer
16.7.5.2.1. Captive
16.7.5.2.2. Merchant
16.7.5.3. South
Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Synthesis
16.7.5.3.1. Synthetic
16.7.5.3.2. Biotech
16.7.5.4. South
Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Product
16.7.5.4.1. mAb
16.7.5.4.2. Hormone
16.7.5.4.3. Biosimilar
16.7.5.5. South
Africa Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Drug
16.7.5.5.1. OTC
16.7.5.5.2. Rx
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest
of Middle East & Africa Active Pharmaceutical Ingredient Market Revenue
(US$ Mn) and Forecasts, By Type
16.7.6.1.1. Innovative
16.7.6.1.2. Generic
16.7.6.2. Rest
of Middle East & Africa Active Pharmaceutical Ingredient Market Revenue
(US$ Mn) and Forecasts, By Manufacturer
16.7.6.2.1. Captive
16.7.6.2.2. Merchant
16.7.6.3. Rest
of Middle East & Africa Active Pharmaceutical Ingredient Market Revenue
(US$ Mn) and Forecasts, By Synthesis
16.7.6.3.1. Synthetic
16.7.6.3.2. Biotech
16.7.6.4. Rest
of Middle East & Africa Active Pharmaceutical Ingredient Market Revenue
(US$ Mn) and Forecasts, By Product
16.7.6.4.1. mAb
16.7.6.4.2. Hormone
16.7.6.4.3. Biosimilar
16.7.6.5. Rest
of Middle East & Africa Active Pharmaceutical Ingredient Market Revenue
(US$ Mn) and Forecasts, By Drug
16.7.6.5.1. OTC
16.7.6.5.2. Rx
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By Type
16.8.3. By
Manufacturer
16.8.4. By
Synthesis
16.8.5. By
Product
16.8.6. By Drug
17. Latin America Active Pharmaceutical Ingredient Market
Analysis and Forecasts, 2019 - 2027
17.1. Overview
17.1.1. Latin
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn)
17.2. Latin
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Type
17.2.1. Innovative
17.2.2. Generic
17.3. Latin
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Manufacturer
17.3.1. Captive
17.3.2. Merchant
17.4. Latin
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Synthesis
17.4.1. Synthetic
17.4.2. Biotech
17.5. Latin
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Product
17.5.1. mAb
17.5.2. Hormone
17.5.3. Biosimilar
17.6. Latin
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Drug
17.6.1. OTC
17.6.2. Rx
17.7. Latin
America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts,
By Country
17.7.1. Brazil
17.7.1.1. Brazil
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
17.7.1.1.1. Innovative
17.7.1.1.2. Generic
17.7.1.2. Brazil
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
17.7.1.2.1. Captive
17.7.1.2.2. Merchant
17.7.1.3. Brazil
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
17.7.1.3.1. Synthetic
17.7.1.3.2. Biotech
17.7.1.4. Brazil
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
17.7.1.4.1. mAb
17.7.1.4.2. Hormone
17.7.1.4.3. Biosimilar
17.7.1.5. Brazil
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
17.7.1.5.1. OTC
17.7.1.5.2. Rx
17.7.2. Argentina
17.7.2.1. Argentina
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Type
17.7.2.1.1. Innovative
17.7.2.1.2. Generic
17.7.2.2. Argentina
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Manufacturer
17.7.2.2.1. Captive
17.7.2.2.2. Merchant
17.7.2.3. Argentina
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Synthesis
17.7.2.3.1. Synthetic
17.7.2.3.2. Biotech
17.7.2.4. Argentina
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By
Product
17.7.2.4.1. mAb
17.7.2.4.2. Hormone
17.7.2.4.3. Biosimilar
17.7.2.5. Argentina
Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and Forecasts, By Drug
17.7.2.5.1. OTC
17.7.2.5.2. Rx
17.7.3. Rest of
Latin America
17.7.3.1. Rest
of Latin America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Type
17.7.3.1.1. Innovative
17.7.3.1.2. Generic
17.7.3.2. Rest
of Latin America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Manufacturer
17.7.3.2.1. Captive
17.7.3.2.2. Merchant
17.7.3.3. Rest
of Latin America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Synthesis
17.7.3.3.1. Synthetic
17.7.3.3.2. Biotech
17.7.3.4. Rest
of Latin America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Product
17.7.3.4.1. mAb
17.7.3.4.2. Hormone
17.7.3.4.3. Biosimilar
17.7.3.5. Rest
of Latin America Active Pharmaceutical Ingredient Market Revenue (US$ Mn) and
Forecasts, By Drug
17.7.3.5.1. OTC
17.7.3.5.2. Rx
17.8. Key
Segment for Channeling Investments
17.8.1. By
Country
17.8.2. By Type
17.8.3. By
Manufacturer
17.8.4. By
Synthesis
17.8.5. By
Product
17.8.6. By Drug
18. Competitive Benchmarking
18.1. Market
Share Analysis, 2018
18.2. Global
Presence and Growth Strategies
18.2.1. Mergers
and Acquisitions
18.2.2. Product
Launches
18.2.3. Investments
Trends
18.2.4. R&D
Initiatives
19. Player Profiles
19.1. AbbVie
Inc.
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. Albemarle
Corporation
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business
Strategies
19.3. Aurobindo
Pharma
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. Boehringer
Ingelheim International GmbH
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key
Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. Bristol-Myers
Squibb Company
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Cipla
Inc.
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key
Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. Dr.
Reddy's Laboratories Ltd.
19.7.1. Company
Details
19.7.2. Company
Overview
19.7.3. Product
Offerings
19.7.4. Key
Developments
19.7.5. Financial
Analysis
19.7.6. SWOT
Analysis
19.7.7. Business
Strategies
19.8. Merck and
Co., Inc.
19.8.1. Company
Details
19.8.2. Company
Overview
19.8.3. Product
Offerings
19.8.4. Key
Developments
19.8.5. Financial
Analysis
19.8.6. SWOT
Analysis
19.8.7. Business
Strategies
19.9. Mylan
N.V.
19.9.1. Company
Details
19.9.2. Company
Overview
19.9.3. Product
Offerings
19.9.4. Key
Developments
19.9.5. Financial
Analysis
19.9.6. SWOT Analysis
19.9.7. Business
Strategies
19.10. Sun
Pharmaceutical Industries Ltd.
19.10.1. Company
Details
19.10.2. Company
Overview
19.10.3. Product
Offerings
19.10.4. Key
Developments
19.10.5. Financial
Analysis
19.10.6. SWOT
Analysis
19.10.7. Business
Strategies
19.11. Teva
Pharmaceutical Industries Ltd.
19.11.1. Company
Details
19.11.2. Company
Overview
19.11.3. Product
Offerings
19.11.4. Key
Developments
19.11.5. Financial
Analysis
19.11.6. SWOT
Analysis
19.11.7. Business
Strategies
19.12. Other
Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.